Open access
Measurable residual disease-negative remission of BRAF-V600Emutated acute myeloid leukemia with dabrafenib and trametinib.
Laura Polmann
C. Schliemann
L. M. Sgonina
Britta Heptner
Christine Eisfeld
J. Marx
J. Mikesch
C. Reicherts
Annalen Bleckmann
Georg Lenz
Matthias Stelljes
Klaus Wethmar
Medicine
Abstract
Not available.